The Women’s Health Initiative did not show that estrogen causes heart disease. It showed that when you start matters. Women who began hormone therapy in their seventies, roughly two decades past menopause, had different results from women who began in their early fifties. In the estrogen-alone arm, women aged 50 to 59 had fewer heart attacks than women on placebo. Across 18 years of follow-up, hormone therapy did not increase death from any cause or from heart disease. Stroke and blood clot risk is genuine at any age, and that finding has not been walked back.

Why one 2002 announcement reshaped a generation

In July 2002 the estrogen-plus-progestin arm of the WHI was stopped early. It reported a small increase in cardiovascular events alongside more strokes and more breast cancer. Prescriptions collapsed within months, and many women who were doing well came off treatment overnight.

The effect itself was modest. Pooled analyses put the increase in cardiovascular events at a hazard ratio of roughly 1.13 for estrogen plus progestin and 1.11 for estrogen alone, both only just clearing statistical significance. What made the headline stick was not the size of the number. It was that a large, well run, placebo-controlled trial had contradicted twenty years of observational optimism, and the correction was reported as a verdict on estrogen itself.

The detail that did not make the headline

The average WHI participant was 63 years old at enrollment. The average age of menopause in North America is 51. The trial largely tested what happens when estrogen is reintroduced to arteries that have gone a decade or more without it, in women who were frequently already carrying atherosclerotic plaque.

When investigators split results by age, a pattern emerged. In the estrogen-alone trial, women aged 50 to 59 did better than placebo on heart attacks over long-term follow-up. Older women did not see that benefit. This is the timing hypothesis, and it had been predicted from primate research in the 1990s, before the WHI ever reported.

Timing was later tested head-on in the ELITE trial, which randomized women to oral estradiol or placebo and stratified them by how far past menopause they were. In women less than six years postmenopause, carotid artery wall thickening slowed measurably. In women ten or more years out, estradiol did nothing at all. The interaction between timing and treatment was statistically significant.

The limitation deserves stating plainly: ELITE measured artery wall thickness, not heart attacks. That is a surrogate marker. It supports the timing idea. It does not prove that starting estradiol early prevents cardiac events.

What eighteen years of follow-up showed

The long-term mortality analysis tracked WHI participants across 18 years with better than 98 percent follow-up. All-cause mortality was 27.1 percent in the hormone therapy group and 27.6 percent on placebo, a hazard ratio of 0.99. Cardiovascular mortality was effectively identical, 8.9 percent versus 9.0 percent.

That is not a claim that hormone therapy extends life. It is the more useful finding that it did not shorten it, even in a trial population older than the one most clinics actually treat. The broader WHI record is a study that answered a narrower question than the one the public heard.

What changed on the label

In February 2026 the FDA approved labeling changes removing boxed warning statements about cardiovascular disease, breast cancer and probable dementia from an initial group of menopausal hormone therapy products, spanning systemic combination therapy, systemic estrogen alone, systemic progestogen alone and topical vaginal estrogen. The agency noted that women who begin within 10 years of the onset of menopause, generally before age 60, show a reduction in all-cause mortality and fractures.

A removed warning is not a recommendation. It means a class-wide warning was judged not to fit the evidence, particularly for younger women and for vaginal estrogen, where systemic absorption is minimal. Individual risk assessment still has to happen.

The risks that did not go away

Stroke and venous thromboembolism. Oral estrogen raises clot risk, and this did not soften with younger age in the way coronary risk did.
Established cardiovascular disease. Hormone therapy is not a treatment for heart disease and is not started in order to prevent it.
The breast cancer signal with combined therapy. The estrogen-alone and estrogen-plus-progestin arms behaved differently, and the combined regimen carries the larger signal.
The formulation gap. The WHI tested oral conjugated equine estrogens and medroxyprogesterone acetate. It did not test transdermal estradiol, micronized progesterone, or pellets. Observational data suggest transdermal routes may carry lower clot risk, but no trial anywhere near the size of the WHI has confirmed that. Anyone telling you pellets are proven safer than the WHI regimen has gone past the evidence.

When to see a clinician rather than keep reading

Seek prompt medical care for chest pain or pressure, particularly with exertion; sudden shortness of breath; one-sided weakness, facial droop or difficulty speaking, which are stroke signs; pain or swelling in one calf; and any vaginal bleeding after menopause.

Making the decision

Hormone therapy is prescribed for symptoms. The cardiovascular data tell you whether prescribing is reasonable, not whether you need it. The Menopause Society advises against it for women with breast cancer, uterine cancer, unexplained uterine bleeding, liver disease, a history of blood clots, or established cardiovascular disease.

If you are within ten years of your last period, under 60, symptomatic, and free of those contraindications, the WHI is a considerably weaker argument against treatment than it has been made to sound. If you are 68, without symptoms, and hoping estrogen will protect your heart, the same trials say no.

Worth reading next: perimenopause vs menopause and questions to ask before you start hormone therapy. Our hormone therapy service explains what an assessment involves, in person in Deerfield Beach or by telehealth across Florida.

Medically reviewed by Krishna Borges, MSN, APRN, FNP-C. This article is for general education and is not a substitute for individual medical advice.